Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111852 · ClinicalTrials.gov registry record · Phase 3
Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
A Phase 3 study of Stroke, Acute, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
- 20
- Study locations
NCT00111852: Completed Phase 3 study of Stroke, Acute, sponsored by Forest Laboratories.
NCT00111852 is a Phase 3 study of Stroke, Acute that has completed, run by Forest Laboratories. The registered enrollment target is 193 participants, below the 622-participant average among 25 other Stroke, Acute trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111852, a Phase 3 study of Stroke, Acute, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke.
Primary Outcome
Improvement of greater than or equal to 8 points from baseline, or NIHSS score less than or equal to 1. The NIHSS score ranges from 0 (least severe) to 42 (more severe).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Desmoteplase
Study Locations (20)
Florida
- Brain Matters, Inc. - Delray Beach
- Melbourne Internal Medicine Associates (MIMA) - Melbourne
- Holmes Regional Medical Center - Melbourne
- Tampa General Hospital - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Boston University Medical Center - Boston
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
Indiana
- Parkview Hospital - Fort Wayne
- Indiana Neuroscience Institute - Indianapolis
Kentucky
- Jewish Hospital Healthcare Services, Inc. - Louisville
- University of Louisville Hospital - Louisville
Ohio
- The Cleveland Clinic Foundation - Cleveland
- The Ohio State University Medical Center - Columbus
Alabama
- Alabama Neurological Institute, Dept. of Neurology - Birmingham
California
- University of California Los Angeles Medical Center - Los Angeles
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00111852 record still lists
NCT00111852 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 622-participant average among 25 other Stroke, Acute trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Stroke, Acute appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00111852 names 20 study sites across 12 states, led by Florida, Massachusetts, Indiana.
Frequently Asked Questions
What is clinical trial NCT00111852 about?
NCT00111852 is a clinical study titled "Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)". The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and al...
What is the current status of trial NCT00111852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2005-04.
What conditions does trial NCT00111852 study?
This clinical trial studies the following conditions: Stroke, Acute.
What interventions are being tested in trial NCT00111852?
The interventions under investigation include: Placebo (DRUG), Desmoteplase (DRUG).
Who is sponsoring clinical trial NCT00111852?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00111852 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00111852's enrollment target sits among peer trials
193 11th of 25 higher than 15 of 25 other Stroke, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Somatic Dysfunction in Patients With Acute Cerebrovascular Disease
RECRUITING
-
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
RECRUITING · NA
-
Focused Intensive Repeated Stepping During Inpatient Rehabilitation Poststroke - A Quality Improvement Project
RECRUITING
-
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
RECRUITING · NA
-
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
RECRUITING · NA
-
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia